阿帕鲁胺的药代动力学药物相互作用:健康男性与去势抵抗性前列腺癌患者临床研究
两项I期研究评估阿帕鲁胺作为底药和促药时的药物相互作用潜力。研究A在45名健康男性中比较单剂阿帕鲁胺240 mg单用或联用CYP3A4强抑制剂伊曲康唑或CYP2C8抑制剂吉非贝齐;研究B在23例去势抵抗性前列腺癌患者中于基线及阿帕鲁胺240 mg每日一次达稳态后给予多种CYP探针及转运体底物。结果显示吉非贝齐使阿帕鲁胺暴露升高68%,阿帕鲁胺显著降低多种底物暴露。
要点
- 阿帕鲁胺主要由CYP2C8代谢,CYP3A4作用较小
- 联用CYP3A4、CYP2C19、CYP2C9、P-gp、BCRP或OATP1B1底物可能导致疗效丧失
- 建议采取适当的缓解策略
核心结论
- 阿帕鲁胺与CYP3A4、CYP2C19、CYP2C9、P-gp、BCRP或OATP1B1底物合用可能导致这些药物活性丧失,建议采取适当缓解策略。
研究设计与样本
- 研究A为随机I期研究,45名健康男性接受单剂阿帕鲁胺240 mg单用或联用伊曲康唑或吉非贝齐。
- 研究B纳入23例去势抵抗性前列腺癌患者,在基线及阿帕鲁胺240 mg每日一次达稳态后给予CYP3A4、CYP2C9、CYP2C19、CYP2C8探针及P-gp、BCRP/OATP1B1转运体底物。
主要发现
- 吉非贝齐使单剂阿帕鲁胺的系统暴露(AUC)增加68%,伊曲康唑对其影响相对不大。
- 阿帕鲁胺使咪达唑仑系统暴露降低92%,奥美拉唑降低85%,S-华法林降低46%,非索非那定降低30%,瑞舒伐他汀降低41%,吡格列酮降低18%。
- 单剂阿帕鲁胺主要经CYP2C8代谢,CYP3A4代谢较少。
临床怎么用
- 合用阿帕鲁胺时需评估CYP3A4、CYP2C19、CYP2C9、P-gp、BCRP或OATP1B1底物类药物疗效下降风险。
- 对上述底物应考虑适当缓解策略,如调整剂量或选择替代药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Two phase I studies assessed the drug-drug interaction potential of apalutamide as a substrate and perpetrator. METHODS: Study A randomized 45 healthy men to single-dose apalutamide 240 mg alone or with strong inhibitors of cytochrome P450 (CYP)3A4 (itraconazole) or CYP2C8 (gemfibrozil). In study B, 23 patients with castration-resistant prostate cancer received probes for CYP3A4 (midazolam), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP2C8 (pioglitazone), and transporter substrates for P-glycoprotein (P-gp) (fexofenadine) and breast cancer resistance protein (BCRP)/organic anion transporting polypeptide (OATP) 1B1 (rosuvastatin) at baseline and after repeat once-daily administration of apalutamide 240 mg to steady state. RESULTS: Systemic exposure (area under the plasma concentration-time curve) to single-dose apalutamide increased 68% with gemfibrozil but was relatively unchanged with itraconazole (study A). Apalutamide reduced systemic exposure to midazolam ↓92%, omeprazole ↓85%, S-warfarin ↓46%, fexofenadine ↓30%, rosuvastatin ↓41%, and pioglitazone ↓18% (study B). After a single dose, apalutamide is predominantly metabolized by CYP2C8, and less by CYP3A4. CONCLUSIONS: Co-administration of apalutamide with CYP3A4, CYP2C19, CYP2C9, P-gp, BCRP or OATP1B1 substrates may cause loss of activity for these medications. Therefore, appropriate mitigation strategies are recommended.
引用
- Duran I, Carles J, Bulat I, et al. Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer. Clin Pharmacokinet. 2020. PMID: 32338345. doi:10.1007/s40262-020-00882-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。